Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Discussion In approximately 50% of all combinations, co-administration of DOACs and SMIs results in moderately potent or potent DDIs. Thus, many relevant DDIs may occur, and this requires interference by the physician to prevent ineffective treatment or increased risk of bleeding caused by DOACs. Edoxaban never causes relevant DDIs that require intervention of physicians, as DDIs are categorised as yellow at most.
Clinical Perspective What Is New? Apixaban is efficacious and safe across the spectrum of weight, including in low- (≤60 kg) and high-weight patients (>120 kg). The superiority on efficacy and safety outcomes of apixaban compared with warfarin persists across weight groups, with even greater reductions in major bleeding in patients with atrial fibrillation with low to normal weight as compared with high weight. What Are the Clinical Implications?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
